Inability of IL-2 and IL-10 to counteract B cell clonal deletion.
The B cell antigen receptor (BCR) delivers inhibitory signals in nascent B cells leading to the establishment of tolerance via clonal deletion or clonal anergy depending upon the type of antigen to which the B cells are exposed. In previous work, it has been demonstrated that activated Th2 cells, as well as some recombinant lymphokines, prevent the inhibition of growth and subsequent cell death induced through the BCR in model B cell lymphomas. Herein, we extend this work to another Th2 lymphokine, IL-10, that in contrast to IL-4 does not interfere with the deletion promoted by IgM crosslinking. The effect of individual lymphokines has also begun to be analyzed in a transgenic model of B cell clonal deletion. To this end, we have administered a recombinant vaccinia virus producing human IL-2 to mice expressing an autoreactive H-2Kk,b-specific transgenic IgMk and found that IL-2 does not abrogate B cell deletion in vivo.
Cuende
E
E
Centro de Biología Molecular (CSIC), Universidad Autónoma de Madrid, Spain.
Kroemer
G
G
Alonso
J M
JM
Nemazee
D
D
Martínez
C
C
Alés-Martínez
J E
JE
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D016923:Cell Death / Q000187:drug effects / Q000276:immunology; D007075:Immunoglobulin M / Q000032:analysis; D016753:Interleukin-10 / Q000276:immunology / Q000494:pharmacology*; D007376:Interleukin-2 / Q000276:immunology / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000276:immunology*; D051379:Mice; D008822:Mice, Transgenic
D000907:Antibodies, Bacterial; D007075:Immunoglobulin M; D007376:Interleukin-2; D016753:Interleukin-10